Differentiating Factors of Abemaciclib Among the CDK 4/6 Inhibitors for Breast Cancer

Hope S. Rugo, MD, discusses the differentiating factors of abemaciclib among the CDK 4/6 inhibitors for breast cancer treatment.

Related Videos
Hope Rugo, MD, FASCO, an expert on breast cancer
Hope Rugo, MD, FASCO, an expert on breast cancer
Hope Rugo, MD, FASCO, an expert on breast cancer
Hope Rugo, MD, FASCO, an expert on breast cancer
Hope Rugo, MD, FASCO, an expert on breast cancer
Hope Rugo, MD, FASCO, an expert on breast cancer
Related Content